Quick Order Cart

Cat. No. ARG43927

ITGB1 Knockout PANC-1 Cell Line

  • Product Type:

    In Stock Cell Lines

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Pancreas

  • Disease:

    Epithelioid carcinoma

The ITGB1 Knockout PANC-1 Cell Line is a CRISPR/Cas9-edited human pancreatic cancer cell model for studying integrin ??1 (ITGB1) function. ITGB1 encodes a cell adhesion receptor that mediates interactions with extracellular matrix proteins, activating downstream pathways involving FAK, Src, PI3K/AKT, and ERK, and regulating processes such as proliferation, survival, and migration. Derived from a KRAS-mutant pancreatic ductal adenocarcinoma, the PANC-1 background is ideal for investigating integrin-driven metastasis and drug resistance. Applications include cell adhesion and invasion assays, 3D tumor model studies, and phospho-signaling analysis to dissect integrin contributions to oncogenic signaling.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    PANC-1

    Sex of Donor

    Male

    Age

    56 years

    Gene Name

    ITGB1

    Gene Identifier

    NCBI Gene ID 3688

    Morphology

    Epithelial-like

    Growth Mode

    Adherent

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The ITGB1 Knockout PANC-1 Cell Line is a CRISPR/Cas9-edited human pancreatic cancer cell line designed for loss-of-function investigation of integrin beta 1 (ITGB1). Generated by targeted disruption of the ITGB1 gene in PANC-1 cells, this constitutive knockout model abrogates ITGB1 protein expression and downstream integrin ??1-mediated functions. It provides a robust system to study adhesion signaling, tumor progression, and drug response mechanisms in a pancreatic ductal adenocarcinoma context.

PANC-1 is a KRAS, TP53, and CDKN2A-mutant pancreatic carcinoma cell line derived from a 56-year-old male. It serves as a clinically relevant model of pancreatic cancer possessing high invasive and metastatic potential. The cell line??s dependency on integrin-mediated adhesion makes it a valid platform to interrogate ITGB1-dependent phenotypes, given its expression of the ??1 integrin subunit and capacity for ECM interactions critical for tumor cell dissemination.

ITGB1 heterodimerizes with multiple ?? integrins (e.g., ITGA1-6, ITGAV) to bind ECM ligands including fibronectin, collagens, and laminins. Ligand engagement recruits talin and kindlin, which activate FAK and Src, triggering the PI3K/AKT and MAPK/ERK cascades. Downstream, Rho GTPases (RhoA, Rac1) reorganize the actin cytoskeleton, while transcription factors AP-1 and NF-??B drive expression of MMPs, cyclin D1, Bcl-2, and Snail. ITGB1 signaling integrates with growth factor cues via co-receptors such as EGFR and is modulated by tetraspanins CD9 and CD81.

In PANC-1 cells, ITGB1 knockout disrupts adhesion to fibronectin and collagen, attenuating FAK and ERK phosphorylation and reducing survival and proliferative outputs. Impaired migration and invasion are anticipated, given the integrin??s role in actin-based motility. In a KRAS-driven tumor model, the absence of ITGB1 signaling may uncouple matrix-dependent survival cues, offering a tool to examine integrin dependence in oncogenic signaling and potential synergies with gemcitabine therapy.

This knockout line is applicable in adhesion, spreading, and migration assays on defined ECM substrates, Boyden chamber invasion assays, and 3D spheroid cultures. Downstream analyses include Western blot detection of phospho-FAK/ERK, immunofluorescence labeling of focal adhesion proteins, RNA-seq transcriptomics, and drug sensitivity testing. Proliferation and apoptosis assays further define the integrin contribution to cell growth. For additional technical specifications or ordering inquiries, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)